Commentary: Can FXR serve as a potential target for COVID-19 prevention?
Acta Pharm Sin B
.
2023 Apr;13(4):1786-1788.
doi: 10.1016/j.apsb.2023.01.023.
Epub 2023 Feb 9.
Authors
Juan Pang
1
,
Jia Nuo Feng
2
3
4
,
Wenhua Ling
1
,
Tianru Jin
2
3
4
Affiliations
1
Division of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
2
Banting and Best Diabetes Centre, Faculty of Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada.
3
Dept. of Physiology, University of Toronto, Toronto, ON M5G 1X8, Canada.
4
Division of Advanced Diagnostics, Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.
PMID:
36785699
PMCID:
PMC9908566
DOI:
10.1016/j.apsb.2023.01.023
No abstract available
Keywords:
ACE2; Bile acid; COVID-19; FXR.